<ul>
<li>想知道 CorMedix 在大约 $11.92 的价格是否仍然是一个明智的投资，还是大部分上涨空间已经被市场定价？这个分析将帮助你从估值的角度而非炒作的角度来框定这个问题。</li>
<li>该股票在过去一周上涨了 1.5%，在过去一个月上涨了 18.3%，年初至今上涨了 45.0%，在三年内上涨了 201.0%。这自然引发了市场是否已经过热或刚刚开始追赶的疑问。</li>
<li>最近对 CorMedix 的关注集中在其将主要感染预防疗法推向市场的进展以及在医院环境中潜在的商业增长。这使得投资者更加关注长期收入和利润率的扩展。同时，监管里程碑和合作讨论也激发了对未来现金流可能远高于过去价格走势的猜测。</li>
<li>在我们的估值框架中，CorMedix 在多个检查中得分为 5 分（满分 6 分），显示出被低估的特征。接下来，我们将解读这在不同估值方法中的实际含义，最后以更全面的方式思考市场可能忽视的内容。</li>
</ul>
<p>CorMedix 在过去一年中实现了 34.4% 的回报。看看这与制药行业的其他公司相比如何。</p>
<h3>方法 1：CorMedix 折现现金流（DCF）分析</h3>
<p>折现现金流模型通过预测公司未来能够产生的现金流并将这些现金流折现回今天的美元价值来估算公司的价值。对于 CorMedix，2 阶段自由现金流到股权模型以过去 12 个月的自由现金流约 7390 万美元为起点，然后结合分析师的预测和 Simply Wall St 的长期外推。</p>
<p>分析师预计未来十年自由现金流将上升到中低 2 亿美元的范围，预计到 2026 年约为 2.258 亿美元，到 2035 年约为 2.389 亿美元，所有这些都折现回现值。将这些折现现金流汇总，模型得出每股内在价值约为 63.07 美元。</p>
<p>与最近的股价约 11.92 美元相比，这一估值表明 CorMedix 的交易价格大约比其基于 DCF 的公允价值低 81.1%，这表明市场可能对该公司长期现金生成潜力的估值相对较低。</p>
<p><strong>结果：被低估</strong></p>
<p>我们的折现现金流（DCF）分析表明 CorMedix 被低估了 81.1%。将其添加到你的观察列表或投资组合中，或发现基于现金流的 918 只被低估的股票。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/dcf"/></p>
<p>截至 2025 年 12 月的 CRMD 折现现金流</p>
<p>前往我们公司报告的估值部分，了解我们如何得出 CorMedix 的公允价值的更多细节。</p>
<h3>方法 2：CorMedix 价格与收益</h3>
<p>对于像 CorMedix 这样盈利的公司，市盈率（PE）是一个有用的衡量标准，因为它将投资者支付的价格直接与公司已经产生的利润联系起来。一般来说，增长较快、风险较低的公司可以合理化更高的市盈率，而增长较慢或风险较高的公司则应转化为较低、更保守的市盈率。</p>
<p>CorMedix 当前的市盈率约为 5.78 倍，远低于制药行业平均水平约 19.98 倍和更广泛的同行平均水平约 33.60 倍。从表面上看，这种折扣看起来像是一个明显的便宜货，但原始的同行和行业比较并不总能捕捉到公司特定的增长前景、盈利能力或风险特征。</p>
<p>这就是 Simply Wall St 的专有公允比率变得相关的地方。对于 CorMedix，公允市盈率估计约为 17.54 倍，反映了其盈利增长前景、行业、利润率、市场资本和风险特征。由于该框架对这些因素进行了标准化，因此比简单的行业或同行比较更具针对性。将这个 17.54 倍的公允比率与当前的 5.78 倍进行比较，表明市场对 CorMedix 的定价大幅低于其基本面可能合理化的水平。</p>
<p><strong>结果：被低估</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/pe-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/pe-multiple-vs-industry"/></p>
<p>截至 2025 年 12 月的 NasdaqGM:CRMD 市盈率</p>
<p>市盈率讲述了一个故事，但如果真正的机会在其他地方呢？发现 1460 家内部人士正在大举押注于爆炸性增长的公司。</p>
<h3>升级你的决策：选择你的 CorMedix 故事</h3>
<p>之前我们提到过，还有一种更好的理解估值的方法，因此让我们向你介绍 Narratives，这是 Simply Wall St 社区页面上的一个简单工具，让你将对 CorMedix 故事的看法与未来收入、收益和利润率的估计联系起来。你可以将这些与公允价值联系起来，然后在新闻、收益和指导到来时不断比较该公允价值与当前股价，以便根据自己的信念决定何时买入或卖出。例如，一个 CorMedix 故事可能偏向看涨，假设 DefenCath 的需求强劲，Melinta 的成功整合和强劲的利润率扩展可以合理化接近 23 美元的公允价值。一个更谨慎的故事可能会关注监管、整合和定价风险，以支持接近 17 美元的公允价值。通过并排查看这两种情况，你可以快速调整自己的预期，而不是仅仅依赖于单一的目标价格。</p>
<p>你认为 CorMedix 的故事还有更多内容吗？前往我们的社区看看其他人怎么说！</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/quote-price"/></p>
<p>NasdaqGM:CRMD 1 年股票价格走势图</p>
<p>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</p>
<p>国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

CRMD

<p>CorMedix 今年迄今已上涨 45%，引发了对其当前估值的质疑。该公司的主要感染预防疗法和潜在收入增长吸引了投资者的关注。折现现金流分析表明，CorMedix 被低估了 81.1%，每股内在价值为 63.07 美元。此外，其市盈率为 5.78 倍，显著低于行业平均水平，表明其可能被低估。总体而言，CorMedix 的交易价格显著低于其公允价值，使其成为一个有吸引力的投资机会</p>

<ul>
<li>Wondering if CorMedix at around $11.92 is still a smart buy after its big run, or if most of the upside has already been priced in? This breakdown will help you frame that question in valuation terms rather than hype.</li>
<li>The stock has climbed 1.5% over the last week, 18.3% in the last month, an impressive 45.0% year to date, and 201.0% over three years. This naturally raises the question of whether the market is now getting ahead of itself or just starting to catch up.</li>
<li>Recent attention around CorMedix has focused on its progress bringing its lead infection prevention therapy to market and the potential commercial ramp in hospital settings. This has sharpened investor focus on long term revenue and margin expansion. At the same time, regulatory milestones and partnership chatter have fueled speculation that future cash flows could be far higher than what past price action alone might suggest.</li>
<li>On our valuation framework, CorMedix scores a strong 5 out of 6 for being undervalued across multiple checks. Next we will unpack what that actually means across different valuation approaches, before finishing with a more holistic way to think about what the market may be missing.</li>
</ul>
<div class="lb-trans"><ul>
<li>想知道 CorMedix 在大约 $11.92 的价格是否仍然是一个明智的投资，还是大部分上涨空间已经被市场定价？这个分析将帮助你从估值的角度而非炒作的角度来框定这个问题。</li>
<li>该股票在过去一周上涨了 1.5%，在过去一个月上涨了 18.3%，年初至今上涨了 45.0%，在三年内上涨了 201.0%。这自然引发了市场是否已经过热或刚刚开始追赶的疑问。</li>
<li>最近对 CorMedix 的关注集中在其将主要感染预防疗法推向市场的进展以及在医院环境中潜在的商业增长。这使得投资者更加关注长期收入和利润率的扩展。同时，监管里程碑和合作讨论也激发了对未来现金流可能远高于过去价格走势的猜测。</li>
<li>在我们的估值框架中，CorMedix 在多个检查中得分为 5 分（满分 6 分），显示出被低估的特征。接下来，我们将解读这在不同估值方法中的实际含义，最后以更全面的方式思考市场可能忽视的内容。</li>
</ul>
</div><p>CorMedix delivered 34.4% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.</p>
<div class="lb-trans"><p>CorMedix 在过去一年中实现了 34.4% 的回报。看看这与制药行业的其他公司相比如何。</p>
</div><h3>Approach 1: CorMedix Discounted Cash Flow (DCF) Analysis</h3>
<div class="lb-trans"><h3>方法 1：CorMedix 折现现金流（DCF）分析</h3>
</div><p>A Discounted Cash Flow model estimates what a company is worth by projecting the cash it can generate in the future and discounting those cash flows back to today in dollar terms. For CorMedix, the 2 Stage Free Cash Flow to Equity model starts with last twelve month free cash flow of about $73.9 million, then layers on analyst forecasts and longer term extrapolations by Simply Wall St.</p>
<div class="lb-trans"><p>折现现金流模型通过预测公司未来能够产生的现金流并将这些现金流折现回今天的美元价值来估算公司的价值。对于 CorMedix，2 阶段自由现金流到股权模型以过去 12 个月的自由现金流约 7390 万美元为起点，然后结合分析师的预测和 Simply Wall St 的长期外推。</p>
</div><p>Analysts see free cash flow rising into the mid to low $200 million range over the next decade, with projections such as about $225.8 million in 2026 and around $238.9 million by 2035, all discounted back to present value. Aggregating these discounted cash flows, the model arrives at an estimated intrinsic value of roughly $63.07 per share.</p>
<div class="lb-trans"><p>分析师预计未来十年自由现金流将上升到中低 2 亿美元的范围，预计到 2026 年约为 2.258 亿美元，到 2035 年约为 2.389 亿美元，所有这些都折现回现值。将这些折现现金流汇总，模型得出每股内在价值约为 63.07 美元。</p>
</div><p>Compared with a recent share price of about $11.92, this valuation suggests CorMedix may be trading at roughly an 81.1% discount to its DCF-derived fair value, indicating the market could be assigning a relatively low value to the company’s long term cash generation potential.</p>
<div class="lb-trans"><p>与最近的股价约 11.92 美元相比，这一估值表明 CorMedix 的交易价格大约比其基于 DCF 的公允价值低 81.1%，这表明市场可能对该公司长期现金生成潜力的估值相对较低。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>结果：被低估</strong></p>
</div><p>Our Discounted Cash Flow (DCF) analysis suggests CorMedix is undervalued by 81.1%. Track this in your watchlist or portfolio, or discover 918 more undervalued stocks based on cash flows.</p>
<div class="lb-trans"><p>我们的折现现金流（DCF）分析表明 CorMedix 被低估了 81.1%。将其添加到你的观察列表或投资组合中，或发现基于现金流的 918 只被低估的股票。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/dcf" alt="" original-src="https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/dcf"/></p>
<p>CRMD Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 CRMD 折现现金流</p>
</div><p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CorMedix.</p>
<div class="lb-trans"><p>前往我们公司报告的估值部分，了解我们如何得出 CorMedix 的公允价值的更多细节。</p>
</div><h3>Approach 2: CorMedix Price vs Earnings</h3>
<div class="lb-trans"><h3>方法 2：CorMedix 价格与收益</h3>
</div><p>For a profitable company like CorMedix, the price to earnings (PE) ratio is a useful yardstick because it links what investors are paying directly to the profits the business is already generating. In general, faster growing, lower risk companies can justify a higher PE multiple, while slower growth or higher risk should translate into a lower, more conservative PE.</p>
<div class="lb-trans"><p>对于像 CorMedix 这样盈利的公司，市盈率（PE）是一个有用的衡量标准，因为它将投资者支付的价格直接与公司已经产生的利润联系起来。一般来说，增长较快、风险较低的公司可以合理化更高的市盈率，而增长较慢或风险较高的公司则应转化为较低、更保守的市盈率。</p>
</div><p>CorMedix currently trades on a PE of about 5.78x, which is well below both the Pharmaceuticals industry average of roughly 19.98x and a broader peer group average of around 33.60x. On the surface, that kind of discount can look like a clear bargain, but raw peer and industry comparisons do not always capture company specific growth prospects, profitability, or risk profile.</p>
<div class="lb-trans"><p>CorMedix 当前的市盈率约为 5.78 倍，远低于制药行业平均水平约 19.98 倍和更广泛的同行平均水平约 33.60 倍。从表面上看，这种折扣看起来像是一个明显的便宜货，但原始的同行和行业比较并不总能捕捉到公司特定的增长前景、盈利能力或风险特征。</p>
</div><p>This is where Simply Wall St’s proprietary Fair Ratio becomes relevant. For CorMedix, the Fair PE Ratio is estimated at about 17.54x, which reflects its earnings growth outlook, industry, profit margins, market cap and risk characteristics. Because this framework normalizes for those factors, it is more tailored than a simple industry or peer comparison. Comparing this Fair Ratio of 17.54x with the current 5.78x suggests the market is pricing CorMedix at a substantial discount to what its fundamentals might justify.</p>
<div class="lb-trans"><p>这就是 Simply Wall St 的专有公允比率变得相关的地方。对于 CorMedix，公允市盈率估计约为 17.54 倍，反映了其盈利增长前景、行业、利润率、市场资本和风险特征。由于该框架对这些因素进行了标准化，因此比简单的行业或同行比较更具针对性。将这个 17.54 倍的公允比率与当前的 5.78 倍进行比较，表明市场对 CorMedix 的定价大幅低于其基本面可能合理化的水平。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>结果：被低估</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/pe-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/pe-multiple-vs-industry"/></p>
<p>NasdaqGM:CRMD PE Ratio as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 NasdaqGM:CRMD 市盈率</p>
</div><p>PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1460 companies where insiders are betting big on explosive growth.</p>
<div class="lb-trans"><p>市盈率讲述了一个故事，但如果真正的机会在其他地方呢？发现 1460 家内部人士正在大举押注于爆炸性增长的公司。</p>
</div><h3>Upgrade Your Decision Making: Choose your CorMedix Narrative</h3>
<div class="lb-trans"><h3>升级你的决策：选择你的 CorMedix 故事</h3>
</div><p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, an easy tool on Simply Wall St’s Community page that lets you connect your view of CorMedix’s story to a set of future revenue, earnings and margin estimates. You can link those to a fair value, and then continuously compare that fair value to the current share price as news, earnings and guidance arrive, so you can decide when to buy or sell based on your own conviction. For example, one CorMedix Narrative might lean bullish, assuming robust demand for DefenCath, successful integration of Melinta and strong margin expansion to justify a fair value near $23. A more cautious Narrative could focus on regulatory, integration and pricing risks to support a fair value closer to $17. By seeing both side by side, you can quickly orient your own expectations instead of relying purely on a single target price.</p>
<div class="lb-trans"><p>之前我们提到过，还有一种更好的理解估值的方法，因此让我们向你介绍 Narratives，这是 Simply Wall St 社区页面上的一个简单工具，让你将对 CorMedix 故事的看法与未来收入、收益和利润率的估计联系起来。你可以将这些与公允价值联系起来，然后在新闻、收益和指导到来时不断比较该公允价值与当前股价，以便根据自己的信念决定何时买入或卖出。例如，一个 CorMedix 故事可能偏向看涨，假设 DefenCath 的需求强劲，Melinta 的成功整合和强劲的利润率扩展可以合理化接近 23 美元的公允价值。一个更谨慎的故事可能会关注监管、整合和定价风险，以支持接近 17 美元的公允价值。通过并排查看这两种情况，你可以快速调整自己的预期，而不是仅仅依赖于单一的目标价格。</p>
</div><p>Do you think there's more to the story for CorMedix? Head over to our Community to see what others are saying!</p>
<div class="lb-trans"><p>你认为 CorMedix 的故事还有更多内容吗？前往我们的社区看看其他人怎么说！</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/quote-price" alt="" original-src="https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/quote-price"/></p>
<p>NasdaqGM:CRMD 1-Year Stock Price Chart</p>
<div class="lb-trans"><p>NasdaqGM:CRMD 1 年股票价格走势图</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

在年初至今上涨 45% 且现金流展望强劲后，Cormedix 是否仍然具有吸引力？